^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Anaplastic Astrocytoma

    Related cancers:
    1d
    IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial. (PubMed, Nat Cancer)
    IDH1-vac-induced T cell responses were detected in the inflamed brain lesion of an IDH1-vac-associated pseudoprogression, whereas no IDH1-vac-induced T cells were found in participants with early progressive disease. The favorable long-term outcome of the NOA16 cohort supports investigating IDH1-vac in persons with newly diagnosed grade 3 and 4 (World Health Organization classification 2021) IDH-mutant astrocytomas in a randomized phase 2 trial (ClinicalTrials.gov identifier: NCT02454634 ).
    P1 data • Journal • First-in-human
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH1 R132
    6d
    Photodynamic diagnosis using 5-aminolevulinic acid in surgery for spinal cord astrocytic tumors: a propensity score-matched comparison with brain tumors. (PubMed, J Neurosurg Spine)
    The findings of this study suggest that PDD may be less effective in the surgery of astrocytic tumors of the spinal cord compared with those of the brain. Verifying the molecular differences of astrocytic tumors between the spinal cord and brain in a large number of cases will be necessary in future studies.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH wild-type
    6d
    TCaP: T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1/2, N=58, Active, not recruiting, Queensland Institute of Medical Research | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2026 --> Oct 2025
    Enrollment closed • Trial primary completion date
    |
    Keytruda (pembrolizumab)
    7d
    NRG-BN005: Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, NRG Oncology | Trial completion date: Jun 2027 --> Jul 2026
    Trial completion date
    |
    temozolomide
    8d
    Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas (clinicaltrials.gov)
    P1/2, N=33, Recruiting, Mayo Clinic | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
    |
    IDH wild-type
    |
    Zynyz (retifanlimab-dlwr)
    16d
    A072301: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer (clinicaltrials.gov)
    P3, N=408, Recruiting, Alliance for Clinical Trials in Oncology | Not yet recruiting --> Recruiting | Initiation date: Oct 2025 --> Jul 2026
    Enrollment open • Trial initiation date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)
    |
    CDKN2A deletion • IDH1 R132
    |
    temozolomide • Voranigo (vorasidenib)
    20d
    Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG (clinicaltrials.gov)
    P2, N=12, Not yet recruiting, Nationwide Children's Hospital
    New P2 trial
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    |
    Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    22d
    Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations. (PubMed, J Neurooncol)
    MolGBM showed comparable unadjusted OS but more favorable adjusted OS than HistGBM, supporting clinical and biological heterogeneity among molecularly defined IDH-WT diffuse glioma. IDH-WT, TERTp-WT lower-grade astrocytic tumors lacking GBM-defining alterations require comprehensive molecular characterization.
    Journal
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • TERT (Telomerase Reverse Transcriptase)
    |
    IDH wild-type
    27d
    Glioblastoma treatment patterns and outcomes over 18 years in an Irish cancer centre. (PubMed, Ir J Med Sci)
    Despite advances in our understanding of the pathogenesis of glioblastoma, the mOS median overall survival in our real-world patient cohort did not improve over time. The findings emphasise the need for ongoing research efforts to improve outcomes in this lethal disease.
    Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    IDH wild-type
    1m
    A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (clinicaltrials.gov)
    P1, N=35, Active, not recruiting, Children's Oncology Group | Trial completion date: Feb 2030 --> Dec 2027 | Trial primary completion date: Apr 2027 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    SurVaxM (SVN53-67/M57-KLH peptide vaccine)
    1m
    Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Northwell Health | Trial completion date: Oct 2027 --> Oct 2029 | Trial primary completion date: Oct 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab)
    1m
    Repeated Super-selective Intraarterial Cerebral Infusion Of Bevacizumab Plus Carboplatin For Treatment Of Relapsed/Refractory GBM And Anaplastic Astrocytoma (clinicaltrials.gov)
    P1/2, N=54, Suspended, Northwell Health | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial primary completion date
    |
    Avastin (bevacizumab) • carboplatin